NEW YORK, Sept. 6, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Blueprint Medicines Corporation (NASDAQ: BPMC) arising from allegations that Blueprint Medicines has disclosed potentially materially misleading business information to the investing public.

SO WHAT: If you have purchased Blueprint Medicines securities, you may be entitled to compensation without payment of expenses or costs through a contingency fee arrangement. Law firm Rosen is preparing a class action lawsuit to recover investor losses.

WHAT TO DO NEXT: To participate in the prospective class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=8186 or call Phillip Kim, Esq. toll free at 866-767-3653 or by email [email protected] or [email protected] for information about the Class Action.

WHAT IS THIS ABOUT: On August 17, 2022, prior to trading hours, Blueprint Medicines announced top-line results from Enrollment Part 2 of its PIONEER clinical trial of AYVAKIT^® (avapritinib) in patients with non-advanced systemic mastocytosis (SM). The results showed a worsening of the absolute symptom score improvement from 15.6 points in this latest study versus 19.7 in phase 1.

As a result of this news, Blueprint Medicine’s stock price fell $7.38 per share, or 10%, due to unusually high trading volume, to close at $61.17 per share on August 17, 2022.

WHY ROSES LAW: We encourage investors to select qualified advisors with a track record in leadership positions. Frequently, companies that issue notices do not have comparable experience, resources, or meaningful recognition from peers. Be wise in choosing a lawyer. The Rosen law firm represents investors worldwide and focuses its practice on securities class actions and shareholder derivatives litigation. Rosen Law Firm has achieved the largest-ever settlement of a securities class action lawsuit against a Chinese company. Law of Roses…